Biocryst Pharmaceuticals (BCRX) Net Cash Flow Growth (1y) (2011 - 2026)
Biocryst Pharmaceuticals (BCRX) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.16 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.72 Bn | 30.78 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.65 Bn | 23.59 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.11 Bn | 20.96 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.30 Bn | 18.50 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.88 Bn | 16.56 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | -1,020.00% |
| 10 | Biocryst Pharmaceuticals | 2.36 Bn | 2.29 Bn | 151.04 Mn | 76,641.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 76,641.12% |
| Dec 31, 2025 | -210.80% |
| Sep 30, 2025 | -120.09% |
| Jun 30, 2025 | 43.68% |
| Mar 31, 2025 | 100.41% |
| Dec 31, 2024 | 121.11% |
| Sep 30, 2024 | 304.95% |
| Jun 30, 2024 | 31.91% |
| Mar 31, 2024 | 82.63% |
| Dec 31, 2023 | -170.47% |
| Sep 30, 2023 | 117.33% |
| Jun 30, 2023 | 93.21% |
| Mar 31, 2023 | -37.30% |
| Dec 31, 2022 | -81.05% |
| Sep 30, 2022 | -138.65% |
| Jun 30, 2022 | -665.62% |
| Mar 31, 2022 | -150.74% |
| Dec 31, 2021 | 72.99% |
| Sep 30, 2021 | 86.03% |
| Jun 30, 2021 | -122.61% |